Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from in...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Gastroenterology Council for Gut and Liver 2025-05-01
Reeks:	Gut and Liver
Onderwerpen:	infliximab; pharmacokinetic model; intravenous; subcutaneous; inflammatory bowel diseases
Online toegang:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl240503
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!